FIZE Medical closes $ 5.3 million Series A financing
MIAMI, April 6, 2021 / PRNewswire / – FIZE Medical, Inc. (“FIZE”) (www.fizemedical.com) recently completed a Series A financing led by Rapha Capital Management, LLC (https://www.raphacap.com), an investment management company located in Miami, Florida, through Rapha Capital Investment IX, LLC (“RCI IX”) (an entity managed by Rapha Capital). RCI IX was joined at the head by MIG FZ LLC, led by Michel ingber MD, director of the Center for Specialized Women’s Health at Garden State Urology, within the Atlantic Health System. This second and final tranche of funding complements the Series A funding of FIZE, initiated with the closing of the first tranche in May 2020 (see Press release). Total $ 5.3 million the funding will be used to continue the development and commercialization of the new FIZE device, the iUO™, the first accurate, automatic, digital and cost-effective device to measure urine flow in real time, replacing the current, manually-managed urinometer bag attached to a standard Foley catheter, which will be made available to hospitals and clinics. doctors around the world. Rapha Capital’s first managed venture capital fund, Rapha Capital BioVentures Fund I also participated in this funding.
Rapha Capital Management is an investment management firm focused on managing strategic investments in early stage, non-public biotechnology companies, previously through Special Purpose Investment Vehicles (“SPIVs”). Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced cancer and robotic surgeon. After leaving practice, Dr Slawin served as a consultant, investor and founder in biotechnology, focusing on disruptive technologies in oncology, T cells and immunotherapy, as well as other cutting-edge healthcare technologies. health. He is the founder of Bellicum Pharmaceuticals, Inc. (“Bellicum”), a NASDAQ listed company, leading Bellicum to a successful $ 161 million IPO in December 2014. He also plays a leading role in several of the investments managed by Rapha Capital in select companies, serving on the board administration. member of 3DBio Therapeutics, Inc (https://3dbiocorp.com/), FIZE Medical, Inc. (www.fizemedical.com) and Demeetra AgBio, Inc. (www.demeetra.com). He was a member of the board of directors and interim CEO of the holding company AsclepiX Therapeutics, Inc. (www.asclepix.com) in 2020, setting up their $ 35 million Series A funding led by Perceptive Xontogeny Venture Fund in mid-2020. Rapha Capital Management manages thirteen legacy SPIVs, Rapha Capital Investment I – XIII. Rapha Capital Management will provide alternative asset management services to its first venture capital fund, launching April 15e, 2021, which will be the vehicle for all future investments managed by Rapha Capital Management.
“FIZE’s basic device, the iUO™, is in itself a giant leap in medicine, conquering the last frontier of patient monitoring by digitizing urine output, measured in real time, and putting it within reach of physicians. Kevin slawin MARYLAND. “The vision of FIZE, to be realized through its pipeline of monitoring products, the iUO PLUS ™, and meUO DUOFLO ™, is poised to truly transform medicine by adding acute kidney disease (AKI) and shock prediction, core temperature and intra-abdominal pressure (IAP) monitoring, fluid balance and use and monitoring of diuretics, real-time urinalysis and management of urinary tract infections, as well as automated intravesical chemotherapy and continuous bladder irrigation therapy (CBI) at the iUO™‘s basic capabilities, ”he added. “It has been gratifying to see how urologists, including our major investors, Drs. Slawin and Ingber, who understand better than anyone the optimal management of Foley’s catheters, respond with such enthusiasm and commitment to our company’s technology and the advancements it offers to their patients, ”said Dror Zerem, CEO of FIZE Medical.
The COVID 19 pandemic has led to an awareness of the need to prioritize technologies that increase the protection of healthcare workers, while improving care for critically ill patients and providing increased efficiency. The FIZE® IUO™ The device meets all of these goals by reducing the number of times a nurse / health worker has to enter an infected patient’s room by automating bladder management.
About FIZE Medical – “Make every drop count“- FIZE® Medical is developing an advanced testing platform to measure key patient health indicators found in their urine, in real time, delivered via FIZE®‘s revolutionary devices, the iUO ™, IUO PLUS ™, and IUO DUOFLO ™. The basic FIZE® device, IUO™, measures urine output in real time in a fully automated manner and integrated with current healthcare IT platforms such as the EMR. FIZE®The advanced product line provides a complete solution by extracting all additional clinically relevant information from urine and delivering it to clinicians at their fingertips. The FIZE® the technology is poised to significantly advance healthcare delivery without the added burden of rising costs. FIZE Medical is headquartered in Modi’in, Israel. For more information visit www.fizemedical.com or email [email protected].
Afight Rapha Capital Management, LLC – Rapha Capital Management, LLC is an investment management firm located in Miami, Florida, focusing on identifying and managing strategic investments in early stage, non-public biotechnology companies. Rapha Capital was founded by its President, Kevin Slawin, MD, a successful and experienced oncology and robotic surgeon, biotechnology consultant, investor and founder focusing on oncology technologies, T cells and immunotherapy, as well as other advanced health technologies. He is the founder of Bellicum Pharmaceuticals, Inc., a company listed on NASDAQ. He is a co-inventor of the FDA, -approved “Prostate health index (phi)” test licensed and marketed by Beckman Coulter and used worldwide. He has published extensively in top medical and scientific journals, including the Journal of the American Medical Association (JAMA), Journal of the National Cancer Institute (JNCI), and the New England Journal of Medicine (NEJM). It has also been regularly listed in America’s Best Doctors For Cancer (Castle Connolly Medical) and America’s best doctors (Woodward / White). In 2003 he was awarded the F. Brantley Scott, Jr., Urology Innovation and Creativity Award.
For more information on Rapha Capital Management, send an email [email protected] or visit https://www.raphacap.com
SOURCE Rapha Capital Management, LLC